These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer].
    Author: Dai MH, Zhao YP, Cai LX, Zhu Y.
    Journal: Zhonghua Wai Ke Za Zhi; 2003 May; 41(5):332-5. PubMed ID: 12892584.
    Abstract:
    OBJECTIVE: To confirm the effect of combined detection of K-ras gene mutation and CA 19-9 level in plasma in the diagnosis of pancreatic carcinoma. METHODS: In 33 patients without pancreatic carcinoma and 15 patients with pancreatic carcinoma, the value of K-ras mutation and CA 19-9 level were examined by enriched polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and radioimmunoassay respectively. The data were analysed with chi(2) test, Fisher's exact test and Kruekal-wall's test. All patients were confirmed pathologically. RESULTS: Eleven of the 15 patients with pancreatic carcinoma and 2 of 10 patients with chronic pancreatitis were found K-ras mutation. CA 19-9 level in patients with pancreatic cancer was significantly higher than that in those with benign disease but with a low specificity. The sensitivity, specificity of combined detection of K-ras gene mutation and CA 19-9 level in the plasma of patients with pancreatic cancer were 66.67% and 97%. There was a significant difference between patients with pancreatic cancer and those without pancreatic cancer. Pathological examination showed atypical hyperplasia in one patient with chronic pancreatitis who had K-ras mutation and higher CA 19-9 level. CONCLUSIONS: Combined detection of K-ras gene mutation and CA 19-9 can be used for adjuvant diagnosis of pancreatic cancer. It is more specific than detection of single K-ras gene mutation or CA 19-9 level in the plasma. The method is complementary to single detection of K-ras gene mutation or CA 19-9 level because it decreases the rate of false-positive diagnosis.
    [Abstract] [Full Text] [Related] [New Search]